PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
MRC1 expression	Small Cell Lung Cancer	MRC1 expression	Small Cell Lung Cancer	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3	RRx-001 Sensitive: C3 – Early Trials RRx-001 Sensitive : C3
CD20 positive	Non-Hodgkin’s Lymphoma	CD20 positive	Non-Hodgkin’s Lymphoma	rituximab + BMS-986351 Sensitive: C3 – Early Trials rituximab + BMS-986351 Sensitive : C3	rituximab + BMS-986351 Sensitive: C3 – Early Trials rituximab + BMS-986351 Sensitive : C3

SIRPA antagonist

Associations(3)